clinical trial · NCT06495723
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Peripheral T Cells Lymphoma (PTCL)LIS1
brief summary
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subtypes of Peripheral TCell Lymphoma (PTCL) and to further evaluate its safety and tolerability at RP2D.
started
Jul 9, 2024
primary completion
Jul 31, 2026
completion
Jul 31, 2027
last updated
Jul 22, 2025
official title
Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol